Related references
Note: Only part of the references are listed.Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions
Koki Uehara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)
Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?
M. Aldea et al.
ESMO OPEN (2023)
Homologous Recombination Deficiencies and Hereditary Tumors
Hideki Yamamoto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise
Brian Healey Bird et al.
DIAGNOSTICS (2022)
The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
Hana Kim et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara et al.
NATURE (2022)
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
Coren A. Milbury et al.
PLOS ONE (2022)
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Jayaprakash Mandal et al.
JOURNAL OF BIOMEDICAL SCIENCE (2022)
Comprehensive molecular profiling broadens treatment options for breast cancer patients
Hitomi Kawaji et al.
CANCER MEDICINE (2021)
Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review
Jasmina Obradovic et al.
MOLECULAR BIOLOGY REPORTS (2021)
Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?
Laura Cortesi et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J. Monk et al.
LANCET ONCOLOGY (2021)
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
Cornelis M. van Tilburg et al.
CANCER DISCOVERY (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Low Rates of Genetic Counseling and Testing in Individuals at Risk for Lynch Syndrome Reported in the National Health Interview Survey
Nolan Faust et al.
GASTROENTEROLOGY (2020)
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
Ryosuke Okamura et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
Hirofumi Ohmura et al.
BRITISH JOURNAL OF CANCER (2020)
Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)
Marilyn M. Li et al.
GENETICS IN MEDICINE (2020)
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud et al.
CANCERS (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
Multiomic analysis of cytokines in immuno-oncology
Vladimir Jurisic
EXPERT REVIEW OF PROTEOMICS (2020)
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S. Antonarakis et al.
JCO PRECISION ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study
Kuniko Sunami et al.
CANCER SCIENCE (2019)
Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group
D. Mandelker et al.
ANNALS OF ONCOLOGY (2019)
A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
Hideaki Bando et al.
BRITISH JOURNAL OF CANCER (2019)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodon et al.
NATURE MEDICINE (2019)
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
Steve Lu et al.
JAMA ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu et al.
CELL (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt et al.
CLINICAL CANCER RESEARCH (2017)
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
J. Vidal et al.
ANNALS OF ONCOLOGY (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies
Hui Chen et al.
CANCERS (2015)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Regional differences in awareness and attitudes regarding genetic testing for disease risk and ancestry
Charles R. Jonassaint et al.
HUMAN GENETICS (2010)
Share Paper
